Novo Nordisk reported DKK13.22B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Bausch Health Companies USD 901M 88M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Merck USD 2.67B 180M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novo Nordisk DKK 13.22B 4.22B Mar/2026
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 83.88M 7.99M Mar/2026
Sanofi EUR 2.63B 307M Jun/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026